CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2%

CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) traded up 2% during mid-day trading on Tuesday . The stock traded as high as $59.62 and last traded at $58.32. 492,650 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 1,672,388 shares. The stock had previously closed at $57.15.

Analysts Set New Price Targets

A number of research analysts have recently commented on CRSP shares. Needham & Company LLC lowered their price target on CRISPR Therapeutics from $90.00 to $88.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Chardan Capital upped their price target on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Barclays dropped their price target on CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. Finally, Oppenheimer decreased their target price on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $73.46.

Get Our Latest Stock Analysis on CRSP

CRISPR Therapeutics Stock Performance

The company’s 50 day moving average price is $57.68 and its 200 day moving average price is $65.57.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. During the same quarter last year, the company posted ($0.67) earnings per share. The business’s revenue was down 99.5% compared to the same quarter last year. Research analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,801 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the transaction, the general counsel now directly owns 60,070 shares in the company, valued at $4,701,078.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, General Counsel James R. Kasinger sold 2,801 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the transaction, the general counsel now owns 60,070 shares in the company, valued at approximately $4,701,078.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,709 shares of company stock worth $3,865,228. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC grew its stake in CRISPR Therapeutics by 12.3% during the third quarter. Private Advisor Group LLC now owns 5,654 shares of the company’s stock worth $254,000 after buying an additional 618 shares during the last quarter. Arizona State Retirement System grew its position in CRISPR Therapeutics by 1.7% during the 3rd quarter. Arizona State Retirement System now owns 21,351 shares of the company’s stock worth $969,000 after acquiring an additional 365 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in CRISPR Therapeutics by 15.6% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 21,998 shares of the company’s stock worth $998,000 after acquiring an additional 2,975 shares during the last quarter. Swiss National Bank increased its holdings in CRISPR Therapeutics by 1.3% during the 3rd quarter. Swiss National Bank now owns 164,800 shares of the company’s stock valued at $7,480,000 after purchasing an additional 2,100 shares in the last quarter. Finally, Spire Wealth Management raised its position in CRISPR Therapeutics by 32.7% in the 3rd quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.